Compare VZLA & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VZLA | MNMD |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 960.2M |
| IPO Year | N/A | N/A |
| Metric | VZLA | MNMD |
|---|---|---|
| Price | $5.19 | $12.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $25.78 |
| AVG Volume (30 Days) | ★ 8.8M | 1.5M |
| Earning Date | 12-09-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $4.70 |
| 52 Week High | $5.61 | $14.43 |
| Indicator | VZLA | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 55.67 |
| Support Level | $5.00 | $12.19 |
| Resistance Level | $5.12 | $13.45 |
| Average True Range (ATR) | 0.27 | 0.70 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 73.46 | 72.07 |
Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).